S&P 500   2,607.26 (-99.73%)
DOW   22,187.22 (-0.63%)
QQQ   192.03 (-0.01%)
AAPL   256.31 (+0.59%)
FB   168.19 (+1.35%)
MSFT   159.18 (-0.66%)
GOOGL   1,158.76 (+1.09%)
AMZN   1,968.86 (+0.25%)
CGC   14.61 (+1.04%)
NVDA   264.97 (-0.23%)
BABA   194.58 (+1.73%)
MU   43.59 (-2.09%)
GE   7.97 (+1.01%)
TSLA   534.50 (+6.45%)
AMD   46.80 (-2.21%)
T   29.49 (-2.48%)
ACB   0.92 (+3.38%)
F   5.02 (-0.20%)
NFLX   376.09 (+1.38%)
BAC   22.02 (-0.09%)
GILD   74.90 (-1.36%)
DIS   98.68 (-1.12%)
S&P 500   2,607.26 (-99.73%)
DOW   22,187.22 (-0.63%)
QQQ   192.03 (-0.01%)
AAPL   256.31 (+0.59%)
FB   168.19 (+1.35%)
MSFT   159.18 (-0.66%)
GOOGL   1,158.76 (+1.09%)
AMZN   1,968.86 (+0.25%)
CGC   14.61 (+1.04%)
NVDA   264.97 (-0.23%)
BABA   194.58 (+1.73%)
MU   43.59 (-2.09%)
GE   7.97 (+1.01%)
TSLA   534.50 (+6.45%)
AMD   46.80 (-2.21%)
T   29.49 (-2.48%)
ACB   0.92 (+3.38%)
F   5.02 (-0.20%)
NFLX   376.09 (+1.38%)
BAC   22.02 (-0.09%)
GILD   74.90 (-1.36%)
DIS   98.68 (-1.12%)
S&P 500   2,607.26 (-99.73%)
DOW   22,187.22 (-0.63%)
QQQ   192.03 (-0.01%)
AAPL   256.31 (+0.59%)
FB   168.19 (+1.35%)
MSFT   159.18 (-0.66%)
GOOGL   1,158.76 (+1.09%)
AMZN   1,968.86 (+0.25%)
CGC   14.61 (+1.04%)
NVDA   264.97 (-0.23%)
BABA   194.58 (+1.73%)
MU   43.59 (-2.09%)
GE   7.97 (+1.01%)
TSLA   534.50 (+6.45%)
AMD   46.80 (-2.21%)
T   29.49 (-2.48%)
ACB   0.92 (+3.38%)
F   5.02 (-0.20%)
NFLX   376.09 (+1.38%)
BAC   22.02 (-0.09%)
GILD   74.90 (-1.36%)
DIS   98.68 (-1.12%)
S&P 500   2,607.26 (-99.73%)
DOW   22,187.22 (-0.63%)
QQQ   192.03 (-0.01%)
AAPL   256.31 (+0.59%)
FB   168.19 (+1.35%)
MSFT   159.18 (-0.66%)
GOOGL   1,158.76 (+1.09%)
AMZN   1,968.86 (+0.25%)
CGC   14.61 (+1.04%)
NVDA   264.97 (-0.23%)
BABA   194.58 (+1.73%)
MU   43.59 (-2.09%)
GE   7.97 (+1.01%)
TSLA   534.50 (+6.45%)
AMD   46.80 (-2.21%)
T   29.49 (-2.48%)
ACB   0.92 (+3.38%)
F   5.02 (-0.20%)
NFLX   376.09 (+1.38%)
BAC   22.02 (-0.09%)
GILD   74.90 (-1.36%)
DIS   98.68 (-1.12%)
Log in

NASDAQ:MTEM - Molecular Templates Stock Price, Forecast & News

$13.25
-0.83 (-5.89 %)
(As of 03/31/2020 12:58 PM ET)
Today's Range
$13.25
Now: $13.25
$14.01
50-Day Range
$11.31
MA: $14.96
$18.26
52-Week Range
$4.51
Now: $13.25
$19.12
Volume3,239 shs
Average Volume299,313 shs
Market Capitalization$604.86 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9
Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.
Read More
Molecular Templates logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MTEM
CUSIP88580720
Phone512-869-1555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.27 million
Book Value$2.79 per share

Profitability

Net Income$-69,420,000.00
Net Margins-311.73%

Miscellaneous

Employees68
Market Cap$604.86 million
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.


Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

How has Molecular Templates' stock been impacted by COVID-19 (Coronavirus)?

Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MTEM shares have increased by 1.1% and is now trading at $13.36. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Molecular Templates?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Molecular Templates.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Molecular Templates.

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc (NASDAQ:MTEM) issued its earnings results on Thursday, March, 12th. The biotechnology company reported ($0.41) EPS for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.05. The biotechnology company earned $6.20 million during the quarter, compared to analysts' expectations of $6.20 million. Molecular Templates had a negative net margin of 311.73% and a negative return on equity of 55.41%. View Molecular Templates' earnings history.

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Shares of Molecular Templates reverse split on the morning of Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for MTEM?

4 Wall Street analysts have issued 12-month price objectives for Molecular Templates' stock. Their forecasts range from $12.00 to $22.00. On average, they anticipate Molecular Templates' stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 32.2% from the stock's current price. View analysts' price targets for Molecular Templates.

Has Molecular Templates been receiving favorable news coverage?

Press coverage about MTEM stock has been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Molecular Templates earned a news impact score of 3.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutMolecular Templates.

Are investors shorting Molecular Templates?

Molecular Templates saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,806,900 shares, an increase of 39.0% from the February 27th total of 1,300,000 shares. Based on an average daily volume of 271,300 shares, the days-to-cover ratio is presently 6.7 days. Currently, 7.0% of the company's shares are short sold. View Molecular Templates' Current Options Chain.

Who are some of Molecular Templates' key competitors?

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Amarin (AMRN), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Alibaba Group (BABA), SLS International (SLS) and ACADIA Pharmaceuticals (ACAD).

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the following people:
  • Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)
  • Ms. Jason S Kim, Pres & COO (Age 44)
  • Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39)

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $13.36.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $609.88 million and generates $22.27 million in revenue each year. The biotechnology company earns $-69,420,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Molecular Templates employs 68 workers across the globe. View additional information about Molecular Templates.

What is Molecular Templates' official website?

The official website for Molecular Templates is http://www.mtem.com/.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]


MarketBeat Community Rating for Molecular Templates (NASDAQ MTEM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  609
MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe MTEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel